38 results on '"Leyland-Jones B"'
Search Results
2. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
3. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis
4. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
5. 67P - Deletions at 1P13.3 is Associated with Significantly Adverse Prognosis in Breast Cancer
6. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease
7. Pharmacologic insights into the future of trastuzumab
8. 1574P - Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates
9. 306PD - PIK3CA alterations in metastatic breast cancer (mBC)
10. 218P - Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
11. 2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies
12. 59P - C8A, a potential predictive marker of trastuzmab benefit, is associated with immunological signatures in MSigDB
13. P068 Sequencing to identify potential targets of resistance to primary therapy
14. P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy
15. P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine
16. 399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study
17. 42P - Low Expression of FGD3, a Putative Guanine Nucleotide Exchange Factor for CDC42, is Prognostic of Poor Outcome in Breast Cancer
18. 375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy
19. 376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study
20. LBA6_PR - Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up
21. 28P Enriched Molecular Function Signatures in Triple Negative and Hormone Receptor Positive Breast Cancer Associated with Metastasis
22. 19P Her2 Extracellular Domain Levels in Patients With Her2-Positive Early Breast Cancer Experiencing Disease Progression: Case-Control Comparison of Samples from the Hera Study
23. PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer
24. PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?
25. S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer
26. 229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells
27. 2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations
28. S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank
29. 586 POSTER Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in Her-2 overexpressing breast cancer cells
30. 274 Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with paclitaxel in breast tumour models
31. 60 Concurrent targeted and chemotherapy treatments is the best way to go
32. Pharmacokinetics of herceptin administered three-weekly compared to weekly — A simulation based on data from the clinical studies
33. Efficacy and safety of three-weekly herceptin with paclitaxel in women with her2-positive metastatic breast cancer: preliminary results of a phase II trial
34. Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer
35. Trastuzumab therapy for the metastatic patient: does the primary match?
36. 1083 A completed phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine followed by accelerated thoracic irradiation, (TRT) in inoperable NSCLC
37. Patient treatment on a compassionate basis: Documentation of high adverse drug reaction rate
38. Ifosfamide stereoselective dichloroethylation and neurotoxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.